<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01674803</url>
  </required_header>
  <id_info>
    <org_study_id>BIO-RESORT</org_study_id>
    <nct_id>NCT01674803</nct_id>
  </id_info>
  <brief_title>Comparison of BIOdegradable Polymer and DuRablE Polymer Drug-eluting Stents in an All COmeRs PopulaTion (BIO-RESORT)</brief_title>
  <acronym>BIO-RESORT</acronym>
  <official_title>Comparison of BIOdegradable Polymer and DuRablE Polymer Drug-eluting Stents in an All COmeRs PopulaTion: Randomized Multicenter Trial in an All Comers Population Treated Within thE NeThErlands 3 (TWENTE 3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardio Research Enschede BV</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardio Research Enschede BV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The introduction of drug-eluting stents (DES) in the treatment of coronary artery disease has
      led to a significant reduction in morbidity. However, the first generation of these devices
      had no positive impact on the mortality after PCI (compared to bare metal stents), which was
      greatly attributed to a somewhat increased incidence of late and very late stent thrombosis.
      Concerns about the role of durable polymers as a potential trigger of inflammation and
      finally adverse events also led to the development of DES with biodegradable coatings, which
      leave after degradation of the coating only a bare metal stent in the vessel wall that does
      not induce an inflammatory response. While such biodegradable polymer DES are increasingly
      used in clinical practice, there is no data available from head-to-head comparisons between
      biodegradable and contemporary third generation durable polymer DES.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 21, 2012</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Actual">August 24, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target vessel failure (TVF)</measure>
    <time_frame>1 year</time_frame>
    <description>Target vessel failure is a combined endpoint of cardiac death, target vessel related myocardial infarction and clinically driven target vessel revascularization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure (TLF)</measure>
    <time_frame>1 year</time_frame>
    <description>Target lesion failure is a combined endpoint of cardiac death, target vessel related myocardial infarction, and clinically driven target lesion revascularization</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3514</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Angina Pectoris</condition>
  <condition>Angina, Unstable</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Stenosis</condition>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>Orsiro</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Synergy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Resolute Integrity</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Orsiro</intervention_name>
    <description>biodegradable polymer sirolimus eluting stent</description>
    <arm_group_label>Orsiro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Synergy</intervention_name>
    <description>biodegradable polymer everolimus eluting stent</description>
    <arm_group_label>Synergy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Resolute Integrity</intervention_name>
    <description>durable polymer zotarolimus-eluting stent</description>
    <arm_group_label>Resolute Integrity</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minimum age of 18 years.

          -  Significant coronary artery disease and lesion(s) eligible for treatment with drug
             eluting stents according to clinical guidelines and/or the operators' judgement.

          -  Capable of providing informed consent.

          -  Patients with all clinical syndromes will be enrolled without any exclusion based on
             number, type, location, or length of lesions to be treated.

        Exclusion Criteria:

          -  Known intolerance to components of one of the stents that will be investigated or
             known intolerance to antithrombotic and/or anticoagulant therapy that prevents
             adherence to dual antiplatelet therapy.

          -  Planned elective surgical procedure necessitating interruption of dual antiplatelet
             therapy during the first 6 months after randomization.

          -  Participation in another randomized drug or device trial before reaching primary
             endpoint.

          -  Adherence to scheduled follow-up is unlikely or life expectancy assumed to be less
             than 1 year.

          -  Known pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Albert Schweitzer Ziekenhuis</name>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2012</study_first_submitted>
  <study_first_submitted_qc>August 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2012</study_first_posted>
  <last_update_submitted>July 21, 2017</last_update_submitted>
  <last_update_submitted_qc>July 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Thorax Centrum Twente</investigator_affiliation>
    <investigator_full_name>prof. C. von Birgelen</investigator_full_name>
    <investigator_title>Professor C. von Birgelen</investigator_title>
  </responsible_party>
  <keyword>drug-eluting stent</keyword>
  <keyword>zotarolimus</keyword>
  <keyword>everolimus</keyword>
  <keyword>sirolimus</keyword>
  <keyword>all comers population</keyword>
  <keyword>target vessel failure</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>durable polymer</keyword>
  <keyword>biodegradable polymer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Coronary Restenosis</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

